Amgen acquires Filgrastim franchise rights from Roche In 100 markets

AmgenAmgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche ("Roche") to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014. Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, Inc. (a joint venture between Amgen and Kirin Holdings Co. Limited, of Japan) in Eastern Europe, Latin America, Asia, the Middle East and Africa since 1989. The franchise generated approximately $200 million in sales in these territories in 2012.

Filgrastim and pegfilgrastim are white blood cell boosting therapeutics used to reduce the risk of infection in patients receiving chemotherapy. They are marketed by Amgen in the United States and Europe under the trade names NEUPOGEN® and Neulasta®, respectively.

"This agreement will enable Amgen to reach more patients around the world with two of our innovative medicines," said Robert A. Bradway, chairman and chief executive officer of Amgen. "The transaction will also allow us to build experience and capacity in countries that will be important in accelerating future growth of Amgen's pipeline products."

Amgen anticipates this deal will be accretive starting in 2014.

Amgen will begin distributing and selling product as soon as practical in countries where the Company has an existing commercial presence. In countries where Amgen does not have a presence, Roche or its distributors will continue to sell and distribute the products for an interim transition period.

"Amgen and Roche will work closely to ensure a seamless transition of the business, marketing authorizations, and most importantly, product supply to the physicians and patients that rely on these important medicines," said Anthony C. Hooper, executive vice president, Global Commercial Operations of Amgen. "Amgen is pleased to have the opportunity to prevent patients receiving myelosuppressive chemotherapy from developing febrile neutropenia in additional markets around the world."

Amgen has grown to be the world's largest independent biotechnology company reaching millions of patients around the world. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them.

Kyowa Hakko Kirin Co., Ltd. of Japan will continue to retain product rights and market filgrastim and pegfilgrastim in some selected Asian territories, including China and Japan.

About Neulasta and NEUPOGEN
Neulasta (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta is not indicated for the mobilization of peripheralblood progenitor cells for hematopoietic stem cell transplantation.

NEUPOGEN (filgrastim) is indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever. A complete blood count and platelet count should be obtained prior to chemotherapy, and twice per week during NEUPOGEN therapy to avoid leukocytosis and to monitor the neutrophil count.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

MSD Innovation Factory is looking for digital solu…

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]